What is the share price of Tatva Chintan Pharma Chem Ltd (TATVA) today?
The share price of TATVA as on 2nd March 2026 is ₹1170.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Tatva Chintan Pharma Chem Ltd (TATVA) share?
The past returns of Tatva Chintan Pharma Chem Ltd (TATVA) share are- Past 1 week: -2.30%
- Past 1 month: 7.67%
- Past 3 months: -18.21%
- Past 6 months: 11.35%
- Past 1 year: 60.86%
- Past 3 years: -38.18%
- Past 5 years: -49.38%
What are the peers or stocks similar to Tatva Chintan Pharma Chem Ltd (TATVA)?
The peers or stocks similar to Tatva Chintan Pharma Chem Ltd (TATVA) include:What is the dividend yield % of Tatva Chintan Pharma Chem Ltd (TATVA) share?
The current dividend yield of Tatva Chintan Pharma Chem Ltd (TATVA) is 0.09.What is the market cap of Tatva Chintan Pharma Chem Ltd (TATVA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Tatva Chintan Pharma Chem Ltd (TATVA) is ₹2737.81 Cr as of 2nd March 2026.What is the 52 week high and low of Tatva Chintan Pharma Chem Ltd (TATVA) share?
The 52-week high of Tatva Chintan Pharma Chem Ltd (TATVA) is ₹1610 and the 52-week low is ₹621.What is the PE and PB ratio of Tatva Chintan Pharma Chem Ltd (TATVA) stock?
The P/E (price-to-earnings) ratio of Tatva Chintan Pharma Chem Ltd (TATVA) is 479.48. The P/B (price-to-book) ratio is 3.71.Which sector does Tatva Chintan Pharma Chem Ltd (TATVA) belong to?
Tatva Chintan Pharma Chem Ltd (TATVA) belongs to the Materials sector & Specialty Chemicals sub-sector.How to buy Tatva Chintan Pharma Chem Ltd (TATVA) shares?
You can directly buy Tatva Chintan Pharma Chem Ltd (TATVA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Tatva Chintan Pharma Chem Ltd
TATVA Share Price
NSE₹1,170.404.34% (-53.10)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
TATVA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
TATVA Performance & Key Metrics
TATVA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 83.55 | 3.71 | 0.09% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 29.39 | 3.36 | 1.53% |
50%
Analysts have suggested that investors can buy this stock
from 2 analysts
Price Upside
Earnings Growth
Rev. Growth
TATVA Company Profile
Tatva Chintan Pharma Chem is engaged in the manufacturing business of chemical products.
FLUOROCHEM
PE Ratio
66.72
66.72
1Y Return
3.67%
3.67%
Buy Reco %
66.67
66.67
NAVINFLUOR
PE Ratio
111.33
111.33
1Y Return
63.82%
63.82%
Buy Reco %
75.00
75.00
AARTIIND
PE Ratio
47.45
47.45
1Y Return
13.49%
13.49%
Buy Reco %
85.00
85.00
VINATIORGA
PE Ratio
36.14
36.14
1Y Return
8.11%
8.11%
Buy Reco %
72.73
72.73
ANURAS
PE Ratio
148.52
148.52
1Y Return
71.68%
71.68%
Buy Reco %
42.86
42.86
TATVA Sentiment Analysis
TATVA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
TATVA Stock Summary · January 2026
Tatva Chintan Pharma Chem Limited demonstrated robust financial health in Q3 FY '26, with significant year-on-year growth in operating revenue and EBITDA, driven by strong demand in the Pharma, Agro, and Specialty Chemicals sectors. Despite challenges from fluctuating chemical prices and production bottlenecks, the company remains optimistic about future growth, particularly with new product commercialization and strategic investments in infrastructure. The ongoing development of a new plant is expected to enhance operational efficiency and profitability, while the transition to innovative technologies in the Agrochemical sector positions the company for long-term success. Management's focus on customer relationships and compliance with evolving regulations, such as Euro 7, further reinforces confidence in achieving projected revenue growth and market stability.
TATVA Stock Growth Drivers
TATVA Stock Growth Drivers
7Strong Financial Performance
Tatva Chintan Pharma Chem Limited has reported impressive financial results, including a 53% year-on-year growth
Successful Product Commercialization
The company has successfully commercialized new agro intermediates, including those based on innovative photochlorination technology,
TATVA Stock Challenges
TATVA Stock Challenges
4Revenue Fluctuations and Unpredictability
The company is experiencing significant fluctuations in revenue, particularly in the SDA segment, which is
Challenges in Inventory Management
The company faces challenges in managing inventory due to demand fluctuations, particularly in the SDA
TATVA Forecast
TATVA Forecasts
Price
Revenue
Earnings
TATVA Share Price Forecast
TATVA Share Price Forecast
2026
Current
₹1,170.40
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹1,170.40
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
TATVA Company Revenue Forecast
TATVA Company Revenue Forecast
2025
Current
₹385.03
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2025
Current
₹385.03
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
TATVA Stock EPS (Earnings Per Share) Forecast
TATVA Stock EPS (Earnings Per Share) Forecast
2025
Current
₹2.44
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹2.44
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
TATVA
TATVA
Income
Balance Sheet
Cash Flow
Quarterly Normal View
TATVA Income Statement
TATVA Income Statement
Quarterly Normal View
| Quarter | sep 2023 | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 97.43 | 85.42 | 102.79 | 106.64 | 83.87 | 85.94 | 108.59 | 118.02 | 124.52 | 133.07 | ||||||||||
Operating & Other expenses | 76.42 | 73.21 | 82.66 | 92.85 | 77.90 | 78.84 | 98.91 | 99.53 | 101.30 | 105.85 | ||||||||||
EBITDA | 21.01 | 12.21 | 20.13 | 13.79 | 5.97 | 7.10 | 9.68 | 18.49 | 23.22 | 27.22 | ||||||||||
| Depreciation/Amortization | 6.78 | 6.58 | 6.23 | 6.67 | 6.81 | 6.92 | 7.26 | 8.97 | 9.05 | 9.07 | ||||||||||
| PBIT | 14.23 | 5.63 | 13.90 | 7.12 | -0.84 | 0.18 | 2.42 | 9.52 | 14.17 | 18.15 | ||||||||||
| Interest & Other Items | 3.01 | 0.38 | 0.21 | 0.31 | 0.17 | 0.42 | 0.39 | 0.41 | 0.51 | 0.49 | ||||||||||
| PBT | 11.22 | 5.25 | 13.69 | 6.81 | -1.01 | -0.24 | 2.03 | 9.11 | 13.66 | 17.66 | ||||||||||
| Taxes & Other Items | 3.43 | 1.79 | 4.07 | 1.60 | -0.35 | -0.38 | 1.00 | 2.45 | 3.75 | 2.49 | ||||||||||
| Net Income | 7.79 | 3.46 | 9.62 | 5.21 | -0.66 | 0.14 | 1.03 | 6.66 | 9.91 | 15.17 | ||||||||||
| EPS | 3.43 | 1.48 | 4.11 | 2.23 | -0.29 | 0.06 | 0.44 | 2.84 | 4.24 | 6.49 |
TATVA Company Updates
FY 2026FY 2026
Investor Presentation
Jan 21PDF
Oct 31PDF
Jul 24PDF
TATVA Stock Peers
TATVA Past Performance & Peer Comparison
TATVA Past Performance & Peer Comparison
Comparing 3 stocks from
MaterialsSpecialty Chemicals
Compare valuation on Screener
MaterialsSpecialty Chemicals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Tatva Chintan Pharma Chem Ltd | 479.48 | 3.71 | 0.09% |
| Gujarat Fluorochemicals Ltd | 66.72 | 4.99 | 0.09% |
| Navin Fluorine International Ltd | 111.33 | 12.23 | 0.11% |
| Aarti Industries Ltd | 47.45 | 2.80 | 0.23% |
TATVA Stock Price Comparison
Compare TATVA with any stock or ETFCompare TATVA with any stock or ETF
TATVA
TATVA Holdings
TATVA Shareholdings
TATVA Promoter Holdings Trend
TATVA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
TATVA Institutional Holdings Trend
TATVA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
TATVA Shareholding Pattern
TATVA Shareholding Pattern
TATVA Shareholding History
TATVA Shareholding History
Foreign Institutions
Mutual Funds Invested in TATVA
Mutual Funds Invested in TATVA
No mutual funds holding trends are available
Top 4 Mutual Funds holding Tatva Chintan Pharma Chem Ltd
| Funds (Top 4) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.1644% | Percentage of the fund’s portfolio invested in the stock 0.42% | Change in the portfolio weight of the stock over the last 3 months -0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 63/69 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2706% | Percentage of the fund’s portfolio invested in the stock 0.45% | Change in the portfolio weight of the stock over the last 3 months -0.94% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 50/59 (-19) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2289% | Percentage of the fund’s portfolio invested in the stock 0.18% | Change in the portfolio weight of the stock over the last 3 months -0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 42/56 (-2) |
Compare 3-month MF holding change on Screener
smallcases containing TATVA stock
smallcases containing TATVA stock
Looks like this stock is not in any smallcase yet.
TATVA Events
TATVA Events
TATVA Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.09%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.85 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
TATVA Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.09%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.85 every year
TATVA Upcoming Dividends
TATVA Upcoming Dividends
No upcoming dividends are available
TATVA Past Dividends
TATVA Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2025
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 12, 2025
Cash Dividend
Ex DateEx DateSep 6, 2024
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 6, 2024
Cash Dividend
Ex DateEx DateSep 8, 2023
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 8, 2023
Cash Dividend
Ex DateEx DateSep 8, 2022
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 8, 2022
TATVA Stock News & Opinions
TATVA Stock News & Opinions
Articles & Videos
Earnings
Tatva Chintan Pharma Chem consolidated net profit rises 10735.71% in the December 2025 quarter
Net profit of Tatva Chintan Pharma Chem rose 10735.71% to Rs 15.17 crore in the quarter ended December 2025 as against Rs 0.14 crore during the previous quarter ended December 2024. Sales rose 52.89% to Rs 131.33 crore in the quarter ended December 2025 as against Rs 85.90 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales131.3385.90 53 OPM %19.418.22 - PBDT26.736.69 300 PBT17.66-0.24 LP NP15.170.14 10736 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Tatva Chintan Pharma Chem to conduct board meeting
Tatva Chintan Pharma Chem will hold a meeting of the Board of Directors of the Company on 21 January 2026.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Tatva Chintan Pharma Chem reports consolidated net profit of Rs 9.92 crore in the September 2025 quarter
Net profit of Tatva Chintan Pharma Chem reported to Rs 9.92 crore in the quarter ended September 2025 as against net loss of Rs 0.66 crore during the previous quarter ended September 2024. Sales rose 47.95% to Rs 123.52 crore in the quarter ended September 2025 as against Rs 83.49 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales123.5283.49 48 OPM %17.986.68 - PBDT22.725.79 292 PBT13.66-1.02 LP NP9.92-0.66 LP Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Tatva Chintan Pharma drops on profit booking
The stock had surged 34.45% over the past eight consecutive sessions, buoyed by renewed buying interest in specialty chemical names. The stock has surged 33.78% in three months, 74.94% in six months and 27.57% in one year. Tatva Chintan Pharma Chem is primarily engaged in manufacturing, sale and distribution of specialty chemicals, viz., phase transfer catalysts (PTC), structure directing agents (SDA), electrolyte salts and solutions (ESS), pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). On a consolidated basis, net profit of Tatva Chintan Pharma Chem rose 27.64% to Rs 6.65 crore while net sales rose 10.81% to Rs 116.86 crore in Q1 June 2025 over Q1 June 2024. The company will consider Q2 September 2025 results on Friday, 31 October 2025. Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Tatva Chintan Pharma Chem to convene board meeting
Tatva Chintan Pharma Chem will hold a meeting of the Board of Directors of the Company on 31 October 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Tatva Chintan Pharma Chem to hold AGM
Tatva Chintan Pharma Chem announced that the Annual General Meeting(AGM) of the company will be held on 26 September 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Spotlight
Tatva Chintan Pharma Chem Ltd leads gainers in 'B' group
Omax Autos Ltd, Mirza International Ltd, Kellton Tech Solutions Ltd and Tainwala Chemicals & Plastics (India) Ltd are among the other gainers in the BSE's 'B' group today, 25 July 2025.Tatva Chintan Pharma Chem Ltd spiked 16.07% to Rs 1180 at 25-Jul-2025 EOD IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 2.75 lakh shares were traded on the counter so far as against the average daily volumes of 11831 shares in the past one month. Omax Autos Ltd soared 15.67% to Rs 127.75. The stock was the second biggest gainer in 'B' group. On the BSE, 5.22 lakh shares were traded on the counter so far as against the average daily volumes of 23015 shares in the past one month. Mirza International Ltd surged 13.95% to Rs 37.5. The stock was the third biggest gainer in 'B' group. On the BSE, 3.12 lakh shares were traded on the counter so far as against the average daily volumes of 31679 shares in the past one month. Kellton Tech Solutions Ltd rose 13.81% to Rs 31.4. The stock was the fourth biggest gainer in 'B' group. On the BSE, 17.82 lakh shares were traded on the counter so far as against the average daily volumes of 1.12 lakh shares in the past one month. Tainwala Chemicals & Plastics (India) Ltd exploded 13.78% to Rs 263.05. The stock was the fifth biggest gainer in 'B' group. On the BSE, 33775 shares were traded on the counter so far as against the average daily volumes of 4587 shares in the past one month. Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Tatva Chintan Pharma Chem consolidated net profit rises 27.64% in the June 2025 quarter
Net profit of Tatva Chintan Pharma Chem rose 27.64% to Rs 6.65 crore in the quarter ended June 2025 as against Rs 5.21 crore during the previous quarter ended June 2024. Sales rose 10.81% to Rs 116.86 crore in the quarter ended June 2025 as against Rs 105.46 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales116.86105.46 11 OPM %14.8311.97 - PBDT18.0713.47 34 PBT9.106.81 34 NP6.655.21 28 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Tatva Chintan Pharma Chem schedules board meeting
Tatva Chintan Pharma Chem will hold a meeting of the Board of Directors of the Company on 24 July 2025.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Tatva Chintan Pharma Chem wins export order of USD 35,55,000
Tatva Chintan Pharma Chem has received an export order worth of USD 35,55,000 (approx. Rs 29.95 crore) excluding tax for supply of Specialty Chemicals under Pharma & Agro Intermediates & Speciality Chemicals (PASC) category, to be delivered in November / December 2025 (Q3 FY26).Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 7.79%, vs industry avg of 10.62%
Over the last 5 years, market share decreased from 0.49% to 0.38%
Over the last 5 years, net income has grown at a yearly rate of -31.47%, vs industry avg of 7.86%